{"title":"Effects of Apigenin on the Apoptosis Index of Atherosclerosis.","authors":"Zhuo-Nan Jia, Bo-Yu Zhang, Zhi-Yuan Gao, Jia-Xing Wang, Han-Bing Liu, Xin-Yang He, Jian-Zhao Wu, Li-Ying Luo, Ze-Hui Zhang, Yi-Xuan Huang, Qian Xu","doi":"10.1097/FJC.0000000000001736","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Recently, apigenin has been widely studied for its antiatherosclerosis properties, but its mechanism remains to be further elucidated. This study aims to evaluate the expression of LOX-1, Bcl-2, and Bax in apigenin-treated atherosclerotic rats and to explore whether apigenin affect the expression of apoptotic genes. We analyzed the relationship between these 3 genes and atherosclerosis based on bioinformatics methods and conducted animal experiments on them. We used a fully automatic analyzer to analyze blood lipid levels and found that apigenin had a good effect on lowering blood lipids. Western blot was used to detect LOX-1 protein, and RT-qPCR was used to detect Bcl-2 and Bax mRNA.The fruit showed that apigenin treatment reduced LOX-1 gene expression while increasing the Bcl-2/Bax ratio. These studies provide an experimental basis for the development of apigenin as a new drug for the treatment of atherosclerosis.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"350-373"},"PeriodicalIF":2.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/FJC.0000000000001736","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract: Recently, apigenin has been widely studied for its antiatherosclerosis properties, but its mechanism remains to be further elucidated. This study aims to evaluate the expression of LOX-1, Bcl-2, and Bax in apigenin-treated atherosclerotic rats and to explore whether apigenin affect the expression of apoptotic genes. We analyzed the relationship between these 3 genes and atherosclerosis based on bioinformatics methods and conducted animal experiments on them. We used a fully automatic analyzer to analyze blood lipid levels and found that apigenin had a good effect on lowering blood lipids. Western blot was used to detect LOX-1 protein, and RT-qPCR was used to detect Bcl-2 and Bax mRNA.The fruit showed that apigenin treatment reduced LOX-1 gene expression while increasing the Bcl-2/Bax ratio. These studies provide an experimental basis for the development of apigenin as a new drug for the treatment of atherosclerosis.
期刊介绍:
Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias.
Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.